background: Freezing/vitrifying and thawing/warming of embryos may impair the successful hatching process of the embryo out of its zona pellucida (ZP) and its following implantation into the uterus. Theoretically, assisted hatching (AH) may facilitate the hatching process and subsequently increase implantation rates (IRs).
Introduction
A successful cryopreservation programme of supernumerary frozen embryos may increase the cumulative delivery rate following treatment with assisted reproductive technology (ART), but it is well known that the implantation potential of a frozen/vitrified-thawed/warmed embryo is lower than that of a fresh embryo. Freezing/vitrifying and thawing/warming procedures may impair successful embryonic hatching out of the zona pellucida (ZP) due to embryonic damage during freezing/vitrifying and zona hardening during thawing/ warming. In theory, assisted hatching (AH) performed in the IVF laboratory after freezing/vitrifying-thawing/warming may assist the natural hatching process in vivo and therefore may have the potential to facilitate embryonic implantation.
Randomized studies investigating the clinical benefit of AH in frozen/thawed embryo transfer cycles (FET) cycles have reported controversial findings regarding clinical benefit (Gabrielsen et al., 2004; Balaban et al., 2006; Ge et al., 2008; Valojerdi et al., 2008) or no effect on the implantation rate (IR) per embryo transferred (Primi et al., 2004; Ng et al., 2005; Petersen et al., 2006; Sifer et al., 2006) .
A Cochrane database (Das et al., 2009) on the effect of AH on frozen-thawed embryos (320 AH cycles and 318 control cycles) included data of four randomized trials (Nagy et al., 1999; Elhelw et al., 2005; Ng et al., 2005; Balaban et al., 2006) , including two studies that had been published in a peer-reviewed journal (Ng et al., 2005; Balaban et al., 2006) . Although a significant improvement was observed on the clinical pregnancy rate (PR) of FET cycles, there was no evidence that AH had an impact on live birth rates (LBRs) (Das et al., 2009) .
Recent changes in Belgian legislation regarding ART (including IVF and ICSI) have limited reimbursement of costs related to laboratory ART procedures (Belgisch Staatsblad, June 2003) and to gonadotrophin medication used for hormonal stimulation (Belgisch Staatsblad, September 2006 ) to a maximum of six oocyte aspiration/ART cycles on a life-time base in women up till their 43rd birthday. In another law, it is also stated that no new oocytes may be removed to create embryos if supernumerary frozen embryos from a previous cycle are available (Belgisch Staatsblad, June 2007) . In view of this legislation, the importance of FET cycles has increased and efforts are needed to increase the IR per frozen/thawed embryo.
In view of insufficient clinical evidence demonstrating the value of AH at the start of our study and in view of the need for higher implantation and LBRs in our ART programme within a series of reimbursed cycles, a prospective randomized controlled trial was performed to evaluate the effect of AH, by modified quarter laser-assisted zona thinning (mQLAZT), in our cryopreservation program. The primary aim was to test the hypothesis that the IR per embryo transferred is higher after transfer of frozen/vitrified-thawed/warmed embryos with thinned ZP after mQLAZT when compared with the transfer of frozen/vitrified-thawed/warmed embryos without mQLAZT.
Materials and Methods

Patients
The study protocol was approved by the Institutional Review Board of the Ethical Committee of our University hospital (trial registration number: ClinicalTrials.govID NCT00593775). All couples with frozen/vitrified embryos were invited to participate in this open-label study. After written informed consent, FET cycles were randomized at the time of thawing/warming using sealed envelopes to determine a simple allocation to the mQLAZT group or to the control group. In the mQLAZT group, AH was done as further described. In the control group, FET was done without any embryonic manipulation. The study was performed between February 2006 and July 2008. The following cycles were excluded from the study: cycles with frozen/vitrified-thawed/warmed embryos biopsied in the context of PGD, embryo reception cycles, cycles with thawed/warmed embryos from unknown frozen origin (after transport from other centre) and cycles with a higher number of embryos transferred than the number of embryos on which mQLAZT was performed. Patients could participate in the study several times with independent randomization for each cycle. Therefore, the outcome was calculated for the total group of study cycles (mQLAZT total; control total) and for the first cycle only (¼ data per woman) in this RCT (mQLAZT first cycle; control first cycle). Sub-analysis of the reproductive outcome was also performed for cycles with embryos frozen on Day 3 with the slow cryopreservation method (the largest group) and for cycles with embryos frozen/vitrified on the different days (Day 1/Day 2/Day 3/Day 5). An intention-to-treat analysis was performed on all randomized cycles.
FET cycles and embryo transfer procedures
An FET cycle was defined as a cycle with cycle monitoring based on the intention of thawing/warming frozen/vitrified embryos and transferring frozen/vitrified-thawed/warmed embryos. Frozen/vitrified-thawed/ warmed embryos were transferred in natural cycles, stimulated cycles (gonadotrophin or clomiphene citrate) or hormonal replacement cycles. In clomiphene-citrate-stimulated cycles, clomiphene citrate (Clomid, Sanofi-Aventis, Gouda, The Netherlands) was given daily (50 or 100 mg) for 5 days from Days 3 to 7 of the menstrual cycle. In gonadotrophinstimulated cycles, 75 IU of urinary gonadotrophins (Menopur, Ferring, Copenhagen, Denmark) was administered daily, starting on Day 2 of the cycle until hCG injection. In both natural and stimulated cycles, the follicular response was monitored by regular vaginal ultrasound and serum estradiol (E 2 ) measurements, and hCG (5000 IU; Pregnyl, Organon, Oss, The Netherlands) was given based on the presence of at least one mature follicle (size .17) and on serum E 2 and LH levels. If serum LH was detected (LH values above 10 IU/ml), hCG 5000 IU was administered on the same day at night. In hormonal replacement cycles, patients received increasing doses (2 mg for 7 days, 4 mg for 5 days, 6 mg for 3 days and 8 mg thereafter) of E 2 (Progynova, Bayer BV, Mijdrecht, The Netherlands) following down-regulation with a GnRH agonist (Buserlin acetate, Suprefact SP, Hoechst, Frankfurt, Germany), and endometrial thickness was monitored by vaginal ultrasound once a week. When the endometrium reached or exceeded 8 mm, the GnRH agonist was stopped and 200 mg of vaginal progesterone (Utrogestan, Besins, Drogenbos, Belgium) was given three times daily. The treatment with E 2 and progesterone was continued at the same dose until serum hCG was determined 2 weeks later and if pregnancy was achieved for a further 6 weeks.
All embryos were thawed/warmed one day before ET and a maximum of three embryos were replaced. In natural and stimulated cycles, the timing of the ET was based on the day of embryo freezing/vitrifying (Day 1, Day 2, Day 3 or Day 5), and on the day of hCG injection, taking into account a spontaneous serum LH surge, if present. Day 0 was defined as the estimated day of ovulation. If no serum LH surge was observed, the day of hCG injection was considered as Day-2 (2 days before estimated ovulation); if an LH surge was observed, we considered the day of hCG injection as Day-1 (1 day before estimated ovulation). Thawed embryos frozen in the pronuclear (2PN) stage as zygotes were transferred on Day 2 after ovulation. Embryos frozen in the cleavage stage 2 or 3 days after oocyte aspiration were both thawed/warmed on Day 2 after ovulation, and transferred on Day 3 after ovulation. Blastocysts were thawed/warmed on Day 4 after ovulation and transferred on Day 5 after ovulation. In hormonal replacement cycles, ET was carried out on Day 4 of progesterone administration for embryos that had been frozen/vitrified on Day 2 or Day 3 after oocyte aspiration during the fresh cycle, and on Day 7 of progesterone administration for embryos that had been frozen/vitrified in the blastocyst stage. All transfers were performed using a Cook embryo replacement catheter (Cook, Syndey IVF Embryo Transfer Catheter, Brisbane, Australia). According to the thawing policy in our centre, the number of embryos that will be thawed/warmed is equal to the number of embryos that will be replaced to the patient. All embryos that were further cleaved after 24 h post thawing/warming or that remained at the same stage as on the day of thawing are transferred. Freezing/vitrifying and thawing/warming procedures Supernumerary embryos of patients undergoing an IVF or ICSI treatment were frozen using the slow freezing procedure (embryos frozen on Day 1, Day 2, Day 3 and Day 5 after oocyte aspiration and insemination) or the vitrification method (embryos frozen on Day 3 and Day 5 after oocyte aspiration and insemination) if their quality was sufficient. Sufficient embryo quality was defined as: 2PN zygotes on Day 1; embryos in ≥2 cell stage with ≤25% fragmentation, no multinucleation and with symmetric to slightly asymmetric blastomeres on Day 2; embryos in ≥6 cell stage with ≤25% fragmentation, no multinucleation and with symmetric to slightly asymmetric blastomeres on Day 3; and blastocysts with a visible inner cell mass and good trophectoderm layer on Day 5.
In the slow freezing procedure, embryos were cryopreserved using a programmable freezer (Planer Products, Sunbury-On-Thames, UK) with commercially available freezing media (Cook, Sydney IVF) using 1,2-propanediol or glycerol as cryoprotectant for embryos and blastocysts, respectively. Embryos were loaded one by one into high security straws (CBS, Cryo Bio System, L'Aigle, France). The freezing program was carried out as follows: starting temperature: 208C; rate of cooling: 28C/ min to 258C; hold at 258C for 10 min; manual seeding; hold at 258C for 10 min; cooling rate: 0.38C/min to 2308C; cooling rate: 508C/min to 21508C. Straws were then removed from the freezing chamber and plunged into the liquid N 2 . In the thawing procedure, the straws were thawed one at a time in a water bath at 378C using commercially available thawing media (Cook, Sydney IVF) and all thawing steps were performed according to the manufacturer's protocol.
In the vitrification procedure, embryos were vitrified using commercially available freezing media (Vitrifreeze, Fertipro, Beernem, Belgium). Briefly, (Day-3-old) embryos and early blastocysts were equilibrated at room temperature for at least 2 min into equilibration solution, while expanding and expanded blastocysts were equilibrated at 378C. The embryos and blastocysts were then transferred to the vitrification solution for respectively 5 and 1 min 30 s. After incubation, embryos were transferred to the second vitrification solution and loaded to the tip of a hemi-straw carrier system in a small volume and then immediately plunged into the liquid N 2 and inserted into a larger pre-cooled straw (CBS, Cryo Bio System) ( Vanderzwalmen et al., 2003) . In the warming procedure, the straws were warmed one at a time using commercially available warming media (VitriThaw, Fertipro, Beernem, Belgium) and all warming steps were performed according to the manufacturer's protocol.
After thawing/warming, embryos were examined for the number/regularity of blastomeres and the degree of fragmentation. Embryos were defined to be survived if ≥50% of the blastomeres had survived the thawing/warming procedure upon inspection immediately after this procedure; embryos were scored as fully intact whether 100% of the blastomeres had survived. After thawing/warming, embryos were kept in culture for 24 h to evaluate their cleavage capacity. Embryos were defined to be further cleaved if the number of blastomeres on the day of transfer exceeded the number of blastomeres on the day of thawing. The percentage of ≥8 cell embryos with ≤10% fragmentation, no multinucleation and with symmetric to slightly asymmetric blastomeres after 24 h of further culture was calculated as a quality indicator in our culture system. Survival of blastocysts was based on the integrity of inner cell mass and trophectoderm cells. Degeneration or arrest development was characterized by darkening of cytoplasm or no re-expansion of the blastocoele 24 h after thawing. The thawed/warmed embryos were further cultured in cleavage medium (Cook, Syndey IVF cleavage medium, Brisbane, Australia) or blastocyst medium (Cook, Syndey IVF blastocyst medium, Brisbane, Australia IVF medium). Tables I and II give an overview of respectively the number and distribution of thawing/warming cycles with embryos frozen/vitrified on different days and of the number and distribution of embryos thawed/ warmed in different stages, for both the total group and the first cycle group in the study. 
Modified quarter laser-assisted zona thinning
mQLAZT was performed with a non-contact 1.48-mm diode laser system (Fertilase w ; MTG, Altdorf, Germany) on an inverted microscope as described before (Debrock et al., 2009) . The technique was based on the method described by Mantoudis et al. (2001) . Briefly, the embryo was stabilized with the holding pipette at the 9 o'clock position before laser manipulation. If possible, the embryo was positioned in such a way that the perivitelline space was widest at the region targeted for ZP thinning ( (Fig. 1A) . For blastocysts, this was not possible ( (Fig. 1B) . Care was taken not to harm the embryo during this procedure. If there was any risk to harm an embryo with a thin ZP, mQLAZT was not performed and the cycle was excluded from the study. The ZP was thinned to about one-third of its initial thickness and for a distance of 1208; i.e. laser thinning was initiated at the 1 o'clock position and consecutive irradiations were generated in a clockwise direction to the 5 o'clock position by releasing 7 -13 consecutive irradiations with an irradiation time being between 3.6 and 9.0 ms (mean + SD, 5.98 + 1.09). Exposure time and number of consecutive irradiations were dependent on the thickness and/or hardness of the ZP. There was no damage detected in any of the laser-treated embryos.
Power calculation and outcome variables
This study was based on the hypothesis that the IR per embryo transferred would be higher after ET of frozen/vitrified-thawed/warmed embryos with thinned ZP after mQLAZT (25%) when compared with ET of frozen/vitrified-thawed/warmed embryos without mQLAZT (15%). The baseline IR per thawed/warmed embryo transferred (15%) was based on the average IR per embryo transferred after the thawing/warming procedure in our centre during 2005 and 2006. The IR was defined according to the WHO ICMART glossary (Zegers-Hochschild et al., 2009) as the number of gestational sacs observed divided by the number of embryos transferred. Therefore, assuming a ¼ 0.05 (power of 80%), it was calculated that 270 embryos were required for transfer in each group to demonstrate a difference in IR per embryo transferred, resulting in a total of 540 embryos for the whole study. The primary outcome variable was the IR per embryo transferred [the presence of a gestational sac [intrauterine (IU) or extrauterine (EU)] on ultrasound at 6-8 weeks of pregnancy]. Secondary outcome variables included the IR with fetal heart beat (FHB), the ongoing IR (at 12 weeks of pregnancy), the LBR per embryo transferred and the PR per ET [defined as a positive b-hCG test (≥25 IU/l) 14-16 days after ovulation or 17 days after the start of progesterone supplementation in a hormone replacement freeze-thaw cycle], the clinical PR [defined as the presence of a gestational sac, IU or EU, on ultrasound at 6 -8 weeks of pregnancy], the ongoing PR [defined as viable pregnancy with FHB at 12 weeks of gestational age] and the LBR per ET. Statistical analysis for significant differences was performed using Fisher's exact x 2 , Mann-Whitney U-test and analysis of variance test. A P-value ,0.05 was considered to be statistically significant.
Results
A total of 647 FET cycles were randomized to either the mQLAZT group (n ¼ 324) or the control group (n ¼ 323). After randomization, more cycles (P ¼ 0.003) were excluded in the mQLAZT group (22/324) than in the control group (6/323) for various reasons, shown in Figure 2 . Consequently, reproductive outcome data were available for 302 cycles in the mQLAZT group and 317 cycles in the control group, and were calculated separately for all study cycles and for the first cycle (in the study) per patient. Both groups were comparable with respect to maternal age at thawing/warming, type of FET cycle, type of infertility, indication for infertility (Table III) , number of embryos transferred, IR, ongoing IR and LBR per embryo transferred, and clinical PR, ongoing PR and LBR per embryo transfer (Table IV) .
In the six cycles excluded from the control total group (Fig. 2) , nine embryos were transferred and one embryo implanted, resulting in an IR/IR with FHB/ongoing IR (at 12 weeks)/LBR of 11.1% (1/9) per embryo transferred; six ETs were performed, resulting in a PR/ clinical pregnancy rate (CPR)/ongoing PR (at 12 weeks)/LBR rate of 16.7% (1/6) per ET. In the 22 cycles excluded from the mQLAZT total group (Fig. 2) , 35 embryos were transferred and three embryos implanted, resulting in an IR of 8.6% (3/35) and an IR with FHB/ongoing IR (at 12 weeks)/LBR of 5.7% (2/35) per embryo transferred; 20 ETs were performed resulting in a PR/CPR of 15% (3/20) and an ongoing PR (at 12 weeks)/LBR of 10% (2/20) per ET.
Intention-to-treat analysis of all randomized cycles (included and excluded from the study) revealed no significant differences between the mQLAZT total and the control total group, respectively, for the IR [12.9% (51/396) Both mQLAZT and control groups were comparable with respect to the number and the distribution of the thawing/warming cycles with embryos frozen/vitrified on different days (d1/d2/d3/d5) (total group: P ¼ 0.27; first cycle group: P ¼ 0.09) ( Table I ). In the total group, 1785 embryos were thawed/warmed with respectively 870 and 915 embryos in the mQLAZT and control group. In the first cycle group, 1266 embryos were thawed/warmed with respectively 613 and 653 embryos in the MQLAZT and the control group. Both mQLAZT and control groups were also comparable with respect to the number and the distribution of the embryos thawed/warmed in different stages (total group: P ¼ 0.94; first cycle group: P ¼ 0.92)( Table II) .
The largest group of embryos thawed were embryos frozen on Day 3 with the slow cryopreservation method (Table II) . Both groups were comparable for survival rate, the number of embryos intact after thawing, the number of embryos further cleaved after 24 h and the number of ≥8c embryos 24 h after thawing (Table V) . No significant differences were observed between mQLAZT and control groups regarding the reproductive outcome in cycles with embryos frozen on Day 3 with the slow cryopreservation method (Table V) .
Although the number of cycles and the number of embryos thawed/ warmed on Day 1/2/3/5 were small (Tables I and II) , sub-analysis was performed for both total and first cycle groups (Table VI) . Both groups were comparable for the survival rate of all embryos except for the survival rate of embryos vitrified/warmed on Day 3 (P ¼ 0.04). Both groups were comparable for the reproductive outcome in cycles with embryos frozen/vitrified on the different days, except for the IR per embryo transferred in the cycles with embryos frozen on Day 1 (P ¼ 0.01).
On a total of 619 and 438 cycles with reproductive outcome for the total and first cycle groups, respectively 8 and 7 thawing cycles were included for patients receiving a thawed embryo from an oocyte donor frozen after a previous fresh oocyte receptor cycle (mQLAZT total: n ¼ 4, control total: n ¼ 4; mQLAZT first cycle: n ¼ 3, control first cycle: n ¼ 4). Transfer of thawed embryos in these cycles resulted in two clinical pregnancies (with delivery) in the mQLAZT groups [total: 50% LBR per transfer (2/4); first cycle: 66.7% LBR per transfer (2/3)] and one clinical pregnancy (with early miscarriage) in both control groups. The IR was 33.3% (2/6), 40% (2/5) and 25% (1/4) in the mQLAZT total, mQLAZT first cycle and control (total and first cycle) groups, respectively.
Discussion
In this RCT, mQLAZT did not improve reproductive outcome in FET cycles. Our results are in agreement with those of some RCTs Tubal factor (%) 10.6 9.8 9.6 8.7
Unexplained (%) 10.6 9.5 12.0 8.3
Other factor (%) 1.7 1.9 1.4 2.2 P-value (mQLAZT total versus control total group and mQLAZT first cycle versus control first cycle group): not significant.
RCTs (as documented in Table VII and Fig. 3 ) between 4.2 and 10% in the control group and 1.6 and 20.1% in the study group. In our study, we did not see an increase in the IR after mQLAZT (16.1% in control first cycle group versus 16.3% in mQLAZT first cycle group), possibly because the IR in our control group was at least 60% higher compared with the IR in the control group reported in other RCTs. Our study also reports the live birth per embryo transferred and per embryo transfer, generally considered (Debrock et al., 2010) as the most important reproductive outcome variables to evaluate a possible benefit of a new treatment in ART cycles. Two other RCTs also reported live births with no significant difference in live births (Petersen et al., 2006; Ge et al., 2008) , although one of these studies did mention a significant increase in the IR (Ge et al., 2008) . It is difficult to compare the RCTs that assessed the value of AH in cryocycles due to considerable heterogeneity regarding the AH Laser-assisted zona thinning in frozen/vitrified-thawed/warmed embryos method used, the day of freezing and thawing, clinical and demographic patient characteristics, sample size and study design. Firstly, AH methods used included mostly laser technology (Primi et al., 2004; Ng et al., 2005 , Balaban et al., 2006 Petersen et al., 2006; Ge et al., 2008; Valojerdi et al., 2008) ; our study), whereas only a few investigators used Acid Tyrode solution (Gabrielsen et al., 2004) or pronase (Sifer et al., 2006) . In the studies using laser technology, the ZP was completely opened (Primi et al., 2004; Valojerdi et al., 2008) or thinned (Ng et al., 2005; Balaban et al., 2006; Petersen et al., 2006; Ge et al., 2008) as in our study (Debrock et al., 2009) . Laser-assisted zona thinning can be done over an area of 908 (Mantoudis et al., 2001) or 1208 (our study), but its exact mechanism and value have never been described in animal models, and potential harmful effects on embryo development cannot be excluded. To what extent technical differences in AH methodology may affect clinical outcome is open for discussion, as it appears that chemical, mechanical, enzymatic and laser techniques for AH lead to a comparable IR and PR (Balaban et al., 2002) . Secondly, variation in day of freezing/thawing and in the method of cryopreservation may influence clinical outcome. In our study, we included all FET cycles with Day 1, Day 2, Day 3 and Day-5-old embryos, whereas other investigators used only Day-2-old embryos (Gabrielsen et al., 2004; Ng et al., 2005; Valojerdi et al., 2008) or Day-3-old embryos (Balaban et al., 2006) or a mixture of Day-2 and Day-3-old embryos (Petersen et al., 2006; Sifer et al., 2006; Ge et al., 2008) or a mixture of Day 1, Day 2 and Day-3-old embryos (Primi et al., 2004) . In our study, we used embryos that were frozen with the slow cryopreservation method and the vitrification method, whereas in the other RCTs, only the slow method was used for freezing (Gabrielsen et al., 2004; Primi et al., 2004; Ng et al., 2005; Balaban et al., 2006; Randomization was performed by first using a randomized table created specifically for the study and then a second randomization by drawing lots at transfer. e Patients were randomly selected, starting with a control group that then was followed by a test group; ZT, zona thinning; ZO, zona opening; embr ET, transferred embryo.
our subgroup analysis of Day 3-old embryos frozen with the slow cryopreservation method, we were unable to confirm the higher IR observed by other investigators after ET of AH embryos that were more strictly selected than in our study (cleavage or morula stage on Day 4, excluding embryos with less than optimal viability) (Balaban et al., 2006;  Table V) . Also, our study was not powered to detect significant differences in IR in this subgroup of embryos. In the subgroup analysis of embryos frozen/vitrified on different days, also no benefit of mQLZAT was noted. Moreover, in the subgroup of cycles with frozen embryos on Day 1, a significantly higher IR per embryo transferred was observed in the control group in the total group analysis, whereas in the first cycle group analysis, this difference was not statistically different anymore. Results may also differ between studies due to variation in the day of ET. In our study, all embryos were cultured for 24 h after thawing to evaluate further cleavage, although also embryos with no continuation of cleavage were transferred in this study. In most other studies, ET was also performed 20-24 h after embryo or zygote thawing (Gabrielsen et al., 2004; Primi et al., 2004; Balaban et al., 2006; Petersen et al., 2006; Sifer et al., 2006) , but in one study (Balaban et al., 2006) , AH was performed only on embryos that showed evidence of cleavage after 24 . In a few studies, thawing and transfer was performed on the same day (Ng et al., 2005; Ge et al., 2008; Valojerdi et al., 2008) . At the start of our study in February 2006, only three randomized studies analyzing the effect of AH on the outcome of FET cycles had been published, with controversial results (Gabrielsen et al., 2004; Primi et al., 2004; Ng et al., 2005) . The first study (Gabrielsen et al., 2004) showed a positive effect of AH on the IR but was pseudo-randomized; i.e. the decision to perform AH or not was based on whether thawing has been carried out on an even or odd date. In the second study, a European multicentre prospective randomized study (Primi et al., 2004) , AH had no benefit in FET cycles. In this study, the AH group was further randomized in a double-blind trial comparing immunosuppressive/antibiotic treatment versus placebo treatment (Primi et al., 2004) . When compared with the control group, there was a marked decrease in IR in the combined AH/placebo group but not in the combined AH/immunosuppressive/antibiotic treatment group (see Table VII ) (Primi et al., 2004) . In the third study (Ng et al., 2005) , no differences in IR were found between AH and control group. Out of these three studies, only one study (Ng et al., 2005) included power calculation, like our study and a few other papers published after the start of our study (Balaban et al., 2006; Sifer et al., 2006) . However, many other published RCTs did not describe a specific hypothesis with power calculation and therefore, the value of these studies may be questioned (Gabrielsen et al., 2004; Primi et al., 2004; Petersen et al., 2006; Ge et al., 2008; Valojerdi et al., 2008) .
In view of power calculation and design and method of AH, our study can best be compared with two other studies (Ng et al., 2005; Balaban et al., 2006) . In one study (Ng et al., 2005) , embryos were not left in culture for evaluation of further cleavage and no positive effect of AH was observed on IR. In the other study (Balaban et al., 2006) , AH was performed only on selected embryos that showed further cleavage, while in our study also embryos without continuation of cleavage were transferred. Nevertheless, in our subgroup of embryos frozen with slow method on Day 3, the IR was 17.4% in our control group compared with only 9.9% in the other study (Balaban et al., 2006) .
In our study, the dropout rate after randomization was higher in the mQLAZT group than in the control group due to several reasons (see Results section). In the mQLAZT group, two cycles were excluded due to technical problems with the laser and seven cycles were excluded due to the risk to harm the embryo with thin ZP. Patients were allowed to participate into the study several times, but possible bias in the results due to multiple participation was overcome by conducting separate analysis of the first cycle results for each woman.
The American Society of Reproductive Medicine has recommended that AH may be clinically useful in patients with poor prognosis, and has suggested that individual ART programmes should evaluate their own unique patient populations in order to determine which subgroups may benefit from AH (ASRM, 2008) . Introduction of a new Belgian law (Belgisch Staatsblad, July 2007) stating that supernumerary embryos need to be thawed before a new oocyte aspiration is allowed to create new embryos has led to a drastic increase of 71% in the number of FET cycles in our centre (436 in 2006 and 745 in 2009) . Due to limitations in the reimbursement of ART cycles in Belgium, the demand for a healthy child within these reimbursed cycles has become very high. Within this study, it was shown in our centre that mQLAZT did not increase implantation and life birth rates in FET cycles. In view of the results of our study and those of other studies discussed already, the use of mQLAZT as a routine technique for patients with frozen-thawed embryos cannot be recommended.
